JNJ-54175446

a brain permeable P2X7 antagonist

Also Known As:

(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoro-2-pyrimidinyl)-4-methyl-1,4,6,7-tetrahydro-5H-(1,2,3)triazolo(4,5-c)pyridin-5-yl)methanone; Methanone, (2-chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoro-2-pyrimidinyl)-1,4,6,7-tetrahydro-4-methyl-5H-1,2,3-triazolo(4,5-c)pyridin-5-yl)-

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - JNJ-54175446: 1
  - Pyridines: 88
    - JNJ-54175446: 1

Related Diseases

1.	Major Depressive Disorder (Major Depressive Disorders) 01/01/2023 - "This was a double-blind, placebo-controlled, randomized study to assess the safety and pharmacokinetics of JNJ-54175446 and explore its effects in patients with single episode and recurrent major depressive disorder (MDD) (N = 69) and baseline total Inventory of Depressive Symptomatology Clinician Rated (IDS-C) > 30. " 01/01/2023 - "Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder."
2.	Anhedonia 01/01/2023 - "However, JNJ-54175446 blunted an acute reduction of anhedonia that occurred as a result of TSD, assessed by the Snaith-Hamilton Pleasure Scale (SHAPS) and the Probabilistic Instrumental Learning Task (PILT)."

Related Drugs and Biologics

1.	Purinergic P2X7 Receptors
2.	purine